News | Radiation Therapy | July 11, 2018

Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy

Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064

Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy

July 11, 2018 — Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to explore the production of the medical radioisotope no-carrier-added (n.c.a.) Lutetium-177. Lutetium-177 is used in targeted radionuclide therapy to treat cancers like neuroendocrine tumors and prostate cancer. It destroys cancer cells while leaving healthy cells unaffected.

Bruce Power is a source of medical radioisotopes, and ITG is a subsidiary of Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies. The two companies signed a Memorandum of Understanding to explore the production of n.c.a. Lutetium-177 at the Bruce Power Site. Bruce Power runs commercially operating reactors (CANDU reactors), that allow the company to meet global supply needs of Lutetium-177 through 2064. Furthermore, ITM has developed a unique methodology to produce a special form of Lutetium-177, n.c.a. Lutetium-177, which the company supplies globally under the brand name EndolucinBeta. Because n.c.a. Lutetium-177 contains no metastable long-lived Lutetium-177m impurities, it provides the highest specific activity of all forms of the Lutetium-177 radioisotope. Its high level of radionuclidic purity ensures more effective and economical waste management, better environmental sustainability and the best preconditions for the radiolabeling of biomolecules.

This partnership aims to meet the medical community’s growing demand for radionuclides for use in targeted radionuclide therapies. N.c.a. Lutetium-177 will be produced at Bruce Power’s CANDU reactors while development, processing and global distribution of n.c.a. Lutetium-177 will be managed by ITM.

For more information:,

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...